
Lannett Company Net Debt | LCI
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 529 M | 499 M | 450 M | 589 M | 674 M | 726 M | 659 M | -199 M | -104 M | -36.2 M | -15.4 M | 2.54 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 726 M | -199 M | 314 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Drug manufacturers industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aurora Cannabis
ACB
|
-95 M | $ 4.46 | 13.78 % | $ 245 M | ||
|
Bausch Health Companies
BHC
|
19.3 B | $ 5.89 | 1.55 % | $ 2.18 B | ||
|
Canopy Growth Corporation
CGC
|
-139 M | $ 0.88 | 1.04 % | $ 262 M | ||
|
China Pharma Holdings
CPHI
|
-162 K | $ 0.65 | 1.57 % | $ 2.79 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-6.5 M | $ 7.09 | 0.27 % | $ 105 M | ||
|
Cronos Group
CRON
|
-790 M | $ 3.25 | 0.78 % | $ 1.25 B | ||
|
Emergent BioSolutions
EBS
|
369 M | $ 7.24 | 14.29 % | $ 387 M | ||
|
Evolus
EOLS
|
94.8 M | $ 7.47 | 4.62 % | $ 482 M | ||
|
Harrow Health
HROW
|
178 M | $ 30.58 | 0.33 % | $ 1.12 B | ||
|
OrganiGram Holdings
OGI
|
-102 M | $ 0.94 | 0.18 % | $ 89.6 M | ||
|
Organogenesis Holdings
ORGO
|
-75.9 M | $ 1.29 | 2.19 % | $ 163 M | ||
|
Pacira BioSciences
PCRX
|
223 M | $ 25.05 | 0.42 % | $ 1.12 B | ||
|
Perrigo Company plc
PRGO
|
3.1 B | $ 14.44 | 1.3 % | $ 2 B | ||
|
Relmada Therapeutics
RLMD
|
-2.5 M | $ 3.48 | 0.68 % | $ 137 M | ||
|
Rockwell Medical
RMTI
|
-730 K | $ 8.23 | 0.93 % | $ 296 M | ||
|
SCYNEXIS
SCYX
|
-19.1 M | $ 5.03 | 1.07 % | $ 251 M | ||
|
Solid Biosciences
SLDB
|
-38.7 M | $ 7.06 | 3.07 % | $ 618 M | ||
|
Sundial Growers
SNDL
|
-82.3 M | $ 1.25 | 0.81 % | $ 323 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-1.78 M | $ 1.22 | 0.81 % | $ 2.05 M | ||
|
Tilray
TLRY
|
-172 M | $ 3.72 | 3.05 % | $ 3.31 B | ||
|
TherapeuticsMD
TXMD
|
-1.39 M | $ 2.01 | 1.46 % | $ 23.3 M | ||
|
Veru
VERU
|
-12.7 M | $ 2.55 | 1.59 % | $ 37.3 M | ||
|
Viatris
VTRS
|
11.3 B | $ 17.62 | 0.11 % | $ 20.2 B | ||
|
cbdMD
YCBD
|
-521 K | $ 0.43 | 0.29 % | $ 1.73 M | ||
|
OptiNose
OPTN
|
-82 M | - | - | $ 1.08 B | ||
|
PetIQ
PETQ
|
329 M | - | 1.64 % | $ 400 M | ||
|
Endo International plc
ENDP
|
7.37 B | - | - | $ 28.9 M | ||
|
Radius Health
RDUS
|
-111 M | - | - | $ 1.42 B | ||
|
Recro Pharma
REPH
|
-6.65 M | - | -4.76 % | $ 65.3 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-22.5 M | - | 0.86 % | $ 117 M | ||
|
Agile Therapeutics
AGRX
|
-676 K | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-11.2 M | - | - | $ 142 M | ||
|
PLx Pharma
PLXP
|
-21.8 M | - | -27.8 % | $ 2.56 M | ||
|
Athenex
ATNX
|
-28.3 M | - | -23.39 % | $ 1.76 M | ||
|
Aerie Pharmaceuticals
AERI
|
-11.1 M | - | - | $ 754 M | ||
|
Tricida
TCDA
|
-7.08 M | - | - | $ 3.25 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-50.3 M | - | - | $ 55.5 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-49.7 M | - | - | $ 2.06 B | ||
|
Evoke Pharma
EVOK
|
-13.4 M | - | - | $ 36.6 M | ||
|
Catalent
CTLT
|
4.58 B | - | - | $ 11.5 B | ||
|
DURECT Corporation
DRRX
|
-8.8 M | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.43 M | - | -39.89 % | $ 27.7 M | ||
|
HEXO Corp.
HEXO
|
-80.4 M | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-934 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
-6.59 M | - | 7.5 % | $ 6.35 M | ||
|
Assertio Holdings
ASRT
|
29.1 M | - | - | $ 150 M | ||
|
Jupiter Wellness
JUPW
|
-21.7 K | - | - | $ 33.6 M | ||
|
Neoleukin Therapeutics
NLTX
|
-101 M | - | - | $ 193 M | ||
|
ProPhase Labs
PRPH
|
549 K | - | - | $ 5.07 M |